A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study

Overview of attention for article published in BMC Cancer, December 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (51st percentile)

So far, Altmetric has seen 1 X post from an account with 1,909 followers.

A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with... https://t.co/IcS5Imy7Da

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.